The Act reauthorizes FDA’s user fee programs but omits several proposed reforms to the FDA regulatory framework, setting the stage for further negotiations in Congress.
Key Points:
..Congress authorized FDA to increase the total amount of annual user fees for all product categories compared to prior user fee authorization programs.
..No material reforms to the Federal Food, Drug, and Cosmetic Act are attached to the reauthorization, although Congress may consider such reforms later this year.
Please see full publication below for more information.